Dabigatran ethyl ester is primarily used as an intermediate in the synthesis of dabigatran, an oral anticoagulant. Dabigatran itself is widely applied in medical settings to prevent and treat thromboembolic disorders. It is particularly effective in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Additionally, it is used for the prevention of venous thromboembolism in patients undergoing hip or knee replacement surgery. The drug works by directly inhibiting thrombin, a key enzyme in the blood coagulation cascade, thereby preventing the formation of blood clots. Its advantages include a fixed dosing regimen, no need for routine blood monitoring, and fewer dietary restrictions compared to traditional anticoagulants like warfarin.